Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CT053 CAR-T in R/R Multiple Myeloma
NCT03975907Phase 2Active, not recruiting
- Sponsor
- CARsgen Therapeutics
- Start
- Jun 2019
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of zevorcabtagene autoleucel in multiple myeloma (MM), sponsored by CARsgen Therapeutics. Started Jun 2019; status: active, not recruiting.
02
Drugs
zevorcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03975907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03975907.